MLC1501 Study Assessing Efficacy in STROke Recovery

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a day, MLC1501 high-dose twice a day, or matching placebo for 24 weeks.

Timeline

Start

2025-01

Primary completion

2028-09

Completion

2028-12

Drugs

Indications